Longitudinal progression of negative symptoms in schizophrenia: A new look at an old problem

Schizophrenia Research

Volumn 105, Issue 1-3, 2008, Pages 188-196

  Kelley, Mary E ^a   Haas, Gretchen L ^b,c   van Kammen, Daniel P ^d  

^a EMORY UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d CHDI Management Inc   (United States)

Author keywords

Longitudinal data; Negative symptoms; Ordinal data; Symptomatology

Indexed keywords

BENZATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; PLACEBO;

ADULT; ANHEDONIA; ARTICLE; BLUNTED AFFECT; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EXTRAPYRAMIDAL SYNDROME; HUMAN; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL ISOLATION; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; COGNITION DISORDERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HALOPERIDOL; HOSPITALIZATION; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 52949152393     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.06.003     Document Type: Article

References (55)

1. Addington J., and Addington D. Positive and negative symptoms of schizophrenia: their course and relationship over time. Schizophr. Res. 5 1 (1991) 51-59
2. Alphs L. An industry perspective on the NIMH consensus statement on negative symptoms. Schizophr. Bull. 32 2 (2006) 225-230
3. Andreasen N.C. Negative symptoms in schizophrenia: definition and reliability. Arch. Gen. Psychiatry 39 7 (1982) 784-788
4. Andreasen N.C., and Olsen S. Negative v positive schizophrenia. Definition and validation. Arch. Gen. Psychiatry 39 7 (1982) 789-794
5. Andreasen N.C., Flaum M., Swayze V.W., Tyrrell G., and Arndt S. Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch. Gen. Psychiatry 47 7 (1990) 615-621
6. APA. Diagnostic and Statistical Manual of Mental Disorders (1987), American Psychiatric Association, Washington, DC
7. Arndt S., Andreasen N.C., Flaum M., Miller D., and Nopoulos P. A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. Arch. Gen. Psychiatry 52 5 (1995) 352-360
8. Bilder R.M., Mukherjee S., Rieder R.O., and Pandurangi A.K. Symptomatic and neuropsychological components of defect states. Schizophr. Bull. 11 3 (1985) 409-419
9. Blalock Jr. H.M. Can we find a genuine ordinal slope analogue?. Sociol. Method 7 (1976) 195-229
10. Buchanan R.W., and Carpenter W.T. Evaluating negative symptom treatment efficacy. In: Keefe R.S.E., and McEvoy J.P. (Eds). Negative Symptom and Cognitive Deficit Treatment Response in Schizophrenia (2001), American Psychiatric Press, Inc., Washington, DC 1-18
11. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., Heresco-Levy U., and Carpenter W.T. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 164 10 (2007) 1593-1602
12. Buckley P.F., and Stahl S.M. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?. Acta Psychiatr. Scand. 115 2 (2007) 93-100
13. Bunney W.E., and Hamburg D.A. Methods for reliable longitudinal observation of behavior: development of a method for systematic observation of emotional behavior on psychiatric wards. Arch. Gen. Psychiatry 9 3 (1963) 280-294
14. Carpenter W.T. Traditional ethics and new sensitivities. Schizophr. Bull. 32 1 (2006) 1-2
15. Carpenter W.T., Heinrichs D.W., and Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry 145 5 (1988) 578-583
16. Carpenter Jr. W.T., Arango C., Buchanan R.W., and Kirkpatrick B. Deficit psychopathology and a paradigm shift in schizophrenia research. Biol. Psychiatry 46 3 (1999) 352-360
17. Crow T.J. Molecular pathology of schizophrenia: more than one disease process?. Br. Med. J. 280 6207 (1980) 66-68
18. Crow T.J. The two-syndrome concept: origins and current status. Schizophr. Bull. 11 3 (1985) 471-486
19. Eaton W.W., Thara R., Federman B., Melton B., and Liang K.Y. Structure and course of positive and negative symptoms in schizophrenia. Arch. Gen. Psychiatry 52 2 (1995) 127-134
20. Elliott P., and Hawthorne G. Imputing missing repeated measures data: how should we proceed?. Aust. N. Z. J. Psychiatry 39 7 (2005) 575-582
21. Erhart S.M., Marder S.R., and Carpenter W.T. Treatment of schizophrenia negative symptoms: future prospects. Schizophr. Bull. 32 2 (2006) 234-237
22. Fenton W.S., and McGlashan T.H. Testing systems for assessment of negative symptoms in schizophrenia.[see comment]. Arch. Gen. Psychiatry 49 3 (1992) 179-184
23. Gibbons R.D., Hedeker D., Elkin I., Waternaux C., Kraemer H.C., Greenhouse J.B., Shea M.T., Imber S.D., Sotsky S.M., and Watkins J.T. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch. Gen. Psychiatry 50 9 (1993) 739-750
24. Goldberg S.C. Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr. Bull. 11 3 (1985) 453-456
25. Gueorguieva R., and Krystal J.H. Move over ANOVA progress in analyzing repeated-measures data and its reflection in papers published in the archives of general psychiatry. Arch. Gen. Psychiatry 61 3 (2004) 310-317
26. Hastie T.J., Botha J.L., and Schnitzler C.M. Regression with an ordered categorical response. Stat. Med. 8 7 (1989) 785-794
27. Hedeker D., and Gibbons R.D. A random-effects ordinal regression model for multilevel analysis. Biometrics 50 4 (1994) 933-944
28. Johnstone E.C., Owens D.G., Frith C.D., and Crow T.J. The relative stability of positive and negative features in chronic schizophrenia. Br. J. Psychiatry 150 (1987) 60-64
29. Kay S.R. Significance of the positive-negative distinction in schizophrenia. Schizophr. Bull. 16 4 (1990) 635-652
30. Keefe R.S., Mohs R.C., Losonczy M.F., Davidson M., Silverman J.M., Kendler K.S., Horvath T.B., Nora R., and Davis K.L. Characteristics of very poor outcome schizophrenia. Am. J. Psychiatry 144 7 (1987) 889-895
31. Keefe R.S., Frescka E., Apter S.H., Davidson M., Macaluso J.M., Hirschowitz J., and Davis K.L. Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. Am. J. Psychiatry 153 6 (1996) 806-811
32. Kelley M.E., van Kammen D.P., and Allen D.N. Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am. J. Psychiatry 156 3 (1999) 406-411
33. Kirkpatrick B., and Fischer B. Subdomains within the negative symptoms of schizophrenia: commentary.[comment]. Schizophr. Bull. 32 2 (2006) 246-249
34. Kirkpatrick B., Fenton W.S., Carpenter Jr. W.T., and Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms.[see comment]. Schizophr. Bull. 32 2 (2006) 214-219
35. Liddle P.F. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy.[see comment]. Br. J. Psychiatry 151 (1987) 145-151
36. Lieberman J.A., Tollefson G., Tohen M., Green A.I., Gur R.E., Kahn R., McEvoy J., Perkins D., Sharma T., Zipursky R., Wei H., Hamer R.M., and Group H.S. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry 160 8 (2003) 1396-1404
37. Lipsitz S.R. Methods for estimating the parameters of a linear model for ordered categorical data. Biometrics 48 1 (1992) 271-281
38. Little R.J.A., and Rubin D.B. Statistical Analysis with Missing Data (2002), Wiley, Hoboken, N.J
39. Marneros A., Deister A., and Rohde A. Validity of the negative/positive dichotomy for schizophrenic disorders under long-term conditions. Schizophr. Res. 7 2 (1992) 117-123
40. McEvoy J.P., Hogarty G.E., and Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry 48 8 (1991) 739-745
41. McGlashan T.H., and Fenton W.S. The positive-negative distinction in schizophrenia: review of natural history validators. Arch. Gen. Psychiatry 49 1 (1992) 63-72
42. McGlashan T.H., and Fenton W.S. Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr. Bull. 19 1 (1993) 71-84
43. Miller D.D., Flaum M., Arndt S., Fleming F., and Andreasen N.C. Effect of antipsychotic withdrawal on negative symptoms in schizophrenia. Neuropsychopharmacology 11 1 (1994) 11-20
44. Mueser K.T., Douglas M.S., Bellack A.S., and Morrison R.L. Assessment of enduring deficit and negative symptom subtypes in schizophrenia. Schizophr. Bull. 17 4 (1991) 565-582
45. Pfohl B., and Winokur G. The micropsychopathology of hebephrenic/catatonic schizophrenia. J. Nerv. Ment. Dis. 171 5 (1983) 296-300
46. Pogue-Geile M.F., and Harrow M. Negative symptoms in schizophrenia: their longitudinal course and prognostic importance. Schizophr. Bull. 11 3 (1985) 427-439
47. Rabe-Hesketh S., Skrondal A., and Pickles A. Reliable estimation of generalized linear mixed models using adaptive quadrature. Stata J. 2 1 (2002) 1-21
48. Rosen W.G., Mohs R.C., Johns C.A., Small N.S., Kendler K.S., Horvath T.B., and Davis K.L. Positive and negative symptoms in schizophrenia. Psychiatry Res. 13 4 (1984) 277-284
49. Spitzer R.L., and Endicott J. Schedule for Affective Disorders and Schizophrenia - Lifetime Version (SADS-L). 3rd edition (1979), New York State Psychiatric Institute, New York
50. Spitzer R.L., Williams J.B.W., Gibbon M., and First M.B. Instruction Manual for the Structured Clinical Interview for DSM-III-R (SCID) (1989), New York State Psychiatric Institute, New York
51. Stahl S.M., and Buckley P.F. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr. Scand. 115 1 (2007) 4-11
52. Tandon R., Goldman R.S., Goodson J., and Greden J.F. Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia.[see comment]. Biol. Psychiatry 27 12 (1990) 1323-1326
53. Tandon R., Ribeiro S.C., DeQuardo J.R., Goldman R.S., Goodson J., and Greden J.F. Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication. Biol. Psychiatry 34 7 (1993) 495-497
54. van Kammen D.P., Peters J., Yao J., Van Kammen W.B., Neylan T., Shaw D., and Linnoila M. Norepinephrine in acute exacerbations of chronic schizophrenia: negative symptoms revisited. Arch. Gen. Psychiatry 47 2 (1990) 161-168
55. Venables P., and Wing J. Level of arousal and the subclassification of schizophrenia. Arch. Gen. Psychiatry 7 8 (1962) 114-119